Cladribine in hairy cell leukemia 17
12. Dearden CE, Matutes E, Hilditch BL, et al. Long-term follow- 20. Au WY, Klasa RJ, Gallagher R, et al. Second malignancies in
up of patients with hairy cell leukemia after treatment with patients with hairy cell leukemia in British Columbia: a 20-year
pentostatin or cladribine. Br J Haematol 1999;106:515–519. experience. Blood 1998;92:1160–1164.
13. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up 21. Kampmeier P, Spielberger R, Dickstein J, et al. Increased
of patients with hairy cell leukemia after treatment with incidence of second neoplasms in patients treated with
cladribine. J Clin Oncol 2003;21:891–896. interferon a 2b for hairy cell leukemia: a clinicopathologic
14. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous assessment. Blood 1994;83:2931–2938.
injections of 2-chlorodeoxyadenosine for symptomatic hairy 22. Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a
cell leukemia. J Clin Oncol 1995;989–995. consequence of nucleoside analog therapy for chronic lymphoid
15. Lauria F, Bocchia M, Marotta G, et al. Weekly administration leukemias. J Clin Oncol 1999;17:2454–2460.
of 2-chlorodeoxyadenosine in patients with hairy-cell leuke- 23. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-
mia: a new treatment schedule effective and safer in preventing up of remission duration, mortality, and second malignancies
infectious complications. Blood 1997;89:1838–1839. in hairy cell leukemia patients treated with pentostatin. Blood
16. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a 2000;96:2981–2986.
weekly versus daily schedule for untreated active hairy cell 24. Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomor-
leukemia: final report from the Polish Adult Leukemia Group phologic analysis of bone marrow biopsies after treatment with
(PALG) of a prospective, randomized, multicenter trial. Blood 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994;
2007;109:3672–3675. 84:4310–4315.
17. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy 25. Wheaton S, Tallman MS, Hakimian D, et al. Minimal
cell leukemia with 2-chlorodeoxyadenosine via the Group C residual disease may predict bone marrow relapse in patients
Protocol mechanism of the National Cancer Institute: a report with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
of 979 patients. J Clin Oncol 1998;16:3007–3015. Blood 1996;87:1556–1560.
18. Saven A, Burian C, Adusumalli J, et al. Filgrastim for 26. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of
cladribine-induced neutropenic fever in patients with hairy minimal residual disease in hairy cell leukemia. Blood 2006;
cell leukemia. Blood 1999;93:2471–2477. 107:4658–4662.
19. Kurzrock R, Strom SS, Estey E, et al. Second cancer risk in 27. Sigal D, Sharpe RW, Burian C, et al. Potential curability of
hairy cell leukemia: analysis of 350 patients. J Clin Oncol cladribine in selected patients with hairy cell leukemia
1997;15:1803–1810. [abstract]. J Clin Oncol 2008;(Suppl): abstract 18010.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46